28th March 2019
Consilium Strategic Communications Advises Sequana Medical NV on its Successful IPO
Consilium supports Euronext listing of innovative medical device company
London, 28 March 2019, Consilium Strategic Communications, a global leader in strategic healthcare communications and investor relations, is delighted to have advised on the successful IPO of Sequana Medical NV which has listed on Euronext Brussels raising EUR 27.5 million. Sequana Medical is now trading on Euronext Brussels under the symbol "SEQUA".
The Consilium Strategic Communications team comprising Amber Fennell, Alexandra Harrison, Sukaina Virji, Melissa Gardiner (London) and Marieke Vermeersch (Belgium), will continue to advise the Company on its financial communications and investor relations as a publicly listed company.
Sequana Medical is a commercial stage medical device company focused on the development of
innovative treatment solutions for the management of liver disease, heart failure, malignant ascites and other fluid imbalance disorders.
The Consilium Strategic Communications team can be contacted via email@example.com or +44 (0)20 3709 5700.
“Sequana Medical is a highly innovative medical device company addressing one of the world’s fastest growing health threats caused by unhealthy lifestyles. We are delighted to have supported such a future-minded company and to have advised the team on the successful IPO. We are enjoying our ongoing relationship with the Sequana team as it operates as a public company.”
Amber FennellPartner and Co-Founder of Consilium Strategic Communications
“Consilium has been a trusted advisor for us throughout the IPO process, helping us craft our message to demonstrate the investment rationale of Sequana Medical and our alfapump® and alfapump® DSR technologies. The team has worked with us to great effect and through its influence with the media, we have successfully reached our target audiences.”
Ian CrosbieChief Executive Officer of Sequana Medical
Consilium Strategic Communications
Mary-Jane Elliott / Amber Fennell / Chris Gardner
Tel: +44(0)20 3709 5700
Follow us: @consiliumhc
About Consilium Strategic Communications
Consilium Strategic Communications is a global leader in strategic healthcare communications and investor relations advisory with offices in Europe and across the US. Consilium's highly-skilled team provides strategic, long-term advice to healthcare companies, Boards, senior decision makers and executives on critical communications and IR programmes and stakeholder challenges. The Company has established deep knowledge across all areas of the global healthcare sector through broad experience in representing international clients spanning the Fortune 500, FTSE100, FTSEurofirst 300 and FTSE250, through to discrete specialist reputation management projects.